FDA Approves New, Once-Weekly Extended-Release Exenatide Injection

Date: 
October, 2017

October 23, 2017. The US Food and Drug Administration (FDA) has approved a new, extended-release formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for adults with type 2 diabetes. The new formulation, called Bydureon BCise, is delivered via a once-weekly, single-dose autoinjector device that continuously releases consistent, therapeutic levels of exenatide. In clinical trials, the drug has been shown to lower A1C levels and promote weight loss, both as monotherapy and in combination with metformin, a sulfonylurea, or a thiazolidinedione. Learn more here.